RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R
N Engl J Med. 2012 366 (3): 207-15

PMID: 22256804 · PMCID: PMC3724537 · DOI:10.1056/NEJMoa1105358

MeSH Terms (20)

Aged Aged, 80 and over Animals Carcinoma, Squamous Cell Female Gene Expression Gene Expression Regulation, Neoplastic Genes, ras Humans Indoles Male Mice Middle Aged Mitogen-Activated Protein Kinase Kinases Mutation Protein Kinase Inhibitors Proto-Oncogene Proteins B-raf Skin Neoplasms Sulfonamides Vemurafenib

Connections (2)

This publication is referenced by other Labnodes entities:

Links